| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Weight Loss | 83 | 2023 | 529 | 9.270 |
Why?
|
| Obesity | 139 | 2021 | 2390 | 8.900 |
Why?
|
| Diabetes Mellitus, Type 2 | 58 | 2022 | 1413 | 5.440 |
Why?
|
| Life Style | 54 | 2021 | 444 | 4.990 |
Why?
|
| Overweight | 30 | 2021 | 377 | 3.830 |
Why?
|
| Mexican Americans | 28 | 2015 | 166 | 3.680 |
Why?
|
| Behavior Therapy | 42 | 2018 | 272 | 3.350 |
Why?
|
| Weight Reduction Programs | 13 | 2018 | 58 | 3.220 |
Why?
|
| Exercise | 40 | 2023 | 866 | 3.140 |
Why?
|
| Diet, Reducing | 29 | 2015 | 90 | 2.160 |
Why?
|
| Health Behavior | 14 | 2018 | 390 | 2.090 |
Why?
|
| Anti-Obesity Agents | 10 | 2016 | 46 | 1.850 |
Why?
|
| Body Mass Index | 53 | 2017 | 1695 | 1.850 |
Why?
|
| Energy Intake | 21 | 2015 | 501 | 1.560 |
Why?
|
| Body Weight | 32 | 2015 | 990 | 1.530 |
Why?
|
| Motor Activity | 13 | 2015 | 508 | 1.490 |
Why?
|
| Diet | 20 | 2013 | 1119 | 1.360 |
Why?
|
| School Health Services | 3 | 2015 | 103 | 1.100 |
Why?
|
| Middle Aged | 117 | 2021 | 28892 | 1.080 |
Why?
|
| Cardiovascular Diseases | 26 | 2020 | 2082 | 1.080 |
Why?
|
| Sweetening Agents | 5 | 2013 | 37 | 1.050 |
Why?
|
| Humans | 228 | 2023 | 131759 | 1.030 |
Why?
|
| Female | 159 | 2023 | 71214 | 1.000 |
Why?
|
| Diet, Fat-Restricted | 7 | 2015 | 37 | 0.910 |
Why?
|
| Patient Education as Topic | 17 | 2017 | 465 | 0.900 |
Why?
|
| Male | 130 | 2023 | 65274 | 0.900 |
Why?
|
| Counseling | 7 | 2013 | 237 | 0.870 |
Why?
|
| Metabolic Syndrome | 6 | 2016 | 363 | 0.860 |
Why?
|
| Feeding Behavior | 17 | 2012 | 724 | 0.850 |
Why?
|
| Lactones | 7 | 2006 | 44 | 0.800 |
Why?
|
| Beverages | 3 | 2013 | 100 | 0.770 |
Why?
|
| Risk Reduction Behavior | 7 | 2015 | 148 | 0.770 |
Why?
|
| Aged | 64 | 2020 | 21259 | 0.770 |
Why?
|
| Adult | 87 | 2023 | 31700 | 0.760 |
Why?
|
| Internet | 4 | 2010 | 423 | 0.750 |
Why?
|
| Bulimia | 6 | 2002 | 16 | 0.750 |
Why?
|
| Patient Compliance | 9 | 2018 | 469 | 0.720 |
Why?
|
| Diabetes Mellitus | 7 | 2019 | 890 | 0.710 |
Why?
|
| Dietary Fats | 15 | 2013 | 276 | 0.700 |
Why?
|
| Estrogens, Conjugated (USP) | 5 | 2011 | 16 | 0.700 |
Why?
|
| Quality of Life | 8 | 2021 | 2115 | 0.670 |
Why?
|
| Cholesterol | 14 | 2013 | 541 | 0.650 |
Why?
|
| Community Health Workers | 2 | 2019 | 82 | 0.640 |
Why?
|
| Physical Fitness | 8 | 2016 | 89 | 0.640 |
Why?
|
| Psychotherapy, Group | 4 | 2017 | 58 | 0.620 |
Why?
|
| Surveys and Questionnaires | 19 | 2014 | 4052 | 0.620 |
Why?
|
| Blood Pressure | 14 | 2021 | 1344 | 0.620 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 2 | 2023 | 404 | 0.610 |
Why?
|
| Hypertension | 9 | 2016 | 1360 | 0.600 |
Why?
|
| Depression | 11 | 2015 | 1352 | 0.600 |
Why?
|
| Health Promotion | 9 | 2011 | 407 | 0.590 |
Why?
|
| Treatment Outcome | 29 | 2017 | 12993 | 0.580 |
Why?
|
| House Calls | 1 | 2019 | 36 | 0.580 |
Why?
|
| Bupropion | 2 | 2016 | 27 | 0.570 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2020 | 143 | 0.570 |
Why?
|
| Postmenopause | 7 | 2011 | 149 | 0.570 |
Why?
|
| Naltrexone | 2 | 2016 | 70 | 0.570 |
Why?
|
| Medically Underserved Area | 1 | 2019 | 88 | 0.560 |
Why?
|
| Combined Modality Therapy | 15 | 2016 | 1260 | 0.550 |
Why?
|
| Fructose | 3 | 2016 | 61 | 0.550 |
Why?
|
| Vegetables | 5 | 2011 | 271 | 0.550 |
Why?
|
| Follow-Up Studies | 29 | 2022 | 5297 | 0.540 |
Why?
|
| Risk Factors | 39 | 2019 | 10961 | 0.530 |
Why?
|
| Texas | 17 | 2019 | 3622 | 0.530 |
Why?
|
| United States | 35 | 2016 | 11812 | 0.530 |
Why?
|
| Cholecalciferol | 3 | 2019 | 20 | 0.510 |
Why?
|
| Metformin | 2 | 2017 | 168 | 0.510 |
Why?
|
| Mobile Applications | 1 | 2018 | 114 | 0.510 |
Why?
|
| Randomized Controlled Trials as Topic | 9 | 2015 | 1253 | 0.500 |
Why?
|
| Health Education | 7 | 2016 | 229 | 0.500 |
Why?
|
| Telemedicine | 2 | 2020 | 523 | 0.500 |
Why?
|
| Nausea | 1 | 2016 | 83 | 0.490 |
Why?
|
| Prediabetic State | 3 | 2019 | 66 | 0.480 |
Why?
|
| Energy Metabolism | 5 | 2015 | 785 | 0.480 |
Why?
|
| Schools | 4 | 2015 | 240 | 0.460 |
Why?
|
| Medroxyprogesterone Acetate | 3 | 2010 | 21 | 0.450 |
Why?
|
| Dietary Supplements | 5 | 2019 | 454 | 0.450 |
Why?
|
| Exercise Therapy | 10 | 2015 | 175 | 0.450 |
Why?
|
| Adolescent | 30 | 2021 | 20987 | 0.440 |
Why?
|
| Blood Glucose | 13 | 2019 | 1103 | 0.440 |
Why?
|
| Lipids | 8 | 2013 | 565 | 0.440 |
Why?
|
| Cholesterol, HDL | 11 | 2014 | 394 | 0.440 |
Why?
|
| Self Report | 5 | 2017 | 562 | 0.420 |
Why?
|
| Hypoglycemic Agents | 2 | 2017 | 475 | 0.410 |
Why?
|
| Vitamin D | 4 | 2019 | 194 | 0.400 |
Why?
|
| Plant Preparations | 1 | 2013 | 15 | 0.400 |
Why?
|
| Adiponectin | 2 | 2015 | 124 | 0.400 |
Why?
|
| Nuts | 1 | 2013 | 15 | 0.400 |
Why?
|
| Arachis | 2 | 2013 | 77 | 0.400 |
Why?
|
| Patient Care Team | 1 | 2017 | 557 | 0.400 |
Why?
|
| Psychometrics | 6 | 2011 | 677 | 0.390 |
Why?
|
| Micronutrients | 1 | 2013 | 61 | 0.390 |
Why?
|
| C-Reactive Protein | 3 | 2013 | 455 | 0.390 |
Why?
|
| Poverty | 4 | 2022 | 456 | 0.390 |
Why?
|
| Family Health | 2 | 2011 | 251 | 0.380 |
Why?
|
| Weight Gain | 6 | 2001 | 384 | 0.380 |
Why?
|
| Child | 30 | 2016 | 26307 | 0.370 |
Why?
|
| Telephone | 2 | 2009 | 116 | 0.360 |
Why?
|
| Body Composition | 6 | 2015 | 550 | 0.360 |
Why?
|
| Body Image | 1 | 2012 | 39 | 0.360 |
Why?
|
| Adolescent Development | 1 | 2012 | 37 | 0.360 |
Why?
|
| Triglycerides | 13 | 2014 | 605 | 0.360 |
Why?
|
| Patient Dropouts | 6 | 2016 | 50 | 0.350 |
Why?
|
| Adipokines | 1 | 2012 | 121 | 0.350 |
Why?
|
| Chewing Gum | 1 | 2011 | 13 | 0.350 |
Why?
|
| Mathematics | 1 | 2011 | 72 | 0.350 |
Why?
|
| Patient Selection | 5 | 2011 | 726 | 0.340 |
Why?
|
| Adiposity | 2 | 2009 | 207 | 0.340 |
Why?
|
| Insulin | 6 | 2013 | 1151 | 0.340 |
Why?
|
| Curcumin | 1 | 2011 | 43 | 0.340 |
Why?
|
| Pain | 3 | 2010 | 439 | 0.330 |
Why?
|
| Family Relations | 1 | 2011 | 75 | 0.330 |
Why?
|
| Estrogen Replacement Therapy | 3 | 2011 | 49 | 0.320 |
Why?
|
| Diet, Sodium-Restricted | 1 | 2010 | 13 | 0.320 |
Why?
|
| Genetic Loci | 2 | 2012 | 359 | 0.320 |
Why?
|
| Self Care | 5 | 2018 | 231 | 0.320 |
Why?
|
| Health Status | 4 | 2003 | 388 | 0.320 |
Why?
|
| Incidence | 14 | 2018 | 3349 | 0.320 |
Why?
|
| Appetite Depressants | 3 | 2008 | 23 | 0.320 |
Why?
|
| Educational Status | 1 | 2011 | 281 | 0.320 |
Why?
|
| Nutritional Sciences | 7 | 2012 | 66 | 0.310 |
Why?
|
| Child Development | 1 | 2012 | 273 | 0.300 |
Why?
|
| Child Behavior | 1 | 2011 | 236 | 0.300 |
Why?
|
| Caloric Restriction | 3 | 2018 | 106 | 0.300 |
Why?
|
| Diet, Carbohydrate-Restricted | 1 | 2009 | 27 | 0.300 |
Why?
|
| Online Systems | 1 | 2008 | 17 | 0.300 |
Why?
|
| Feeding and Eating Disorders | 3 | 2017 | 74 | 0.290 |
Why?
|
| Fatty Liver | 1 | 2011 | 220 | 0.290 |
Why?
|
| Regression Analysis | 6 | 2017 | 773 | 0.290 |
Why?
|
| Occupational Health | 1 | 2008 | 47 | 0.290 |
Why?
|
| Obesity, Morbid | 1 | 2011 | 233 | 0.290 |
Why?
|
| Cost-Benefit Analysis | 5 | 2021 | 544 | 0.280 |
Why?
|
| Residence Characteristics | 2 | 2011 | 293 | 0.280 |
Why?
|
| Insulin Resistance | 4 | 2009 | 681 | 0.270 |
Why?
|
| Factor Analysis, Statistical | 4 | 2003 | 235 | 0.270 |
Why?
|
| Research Design | 4 | 2014 | 723 | 0.260 |
Why?
|
| Diet Therapy | 3 | 2015 | 41 | 0.260 |
Why?
|
| Diabetes Complications | 3 | 2012 | 199 | 0.260 |
Why?
|
| Emigration and Immigration | 3 | 2003 | 81 | 0.260 |
Why?
|
| Breast Neoplasms | 4 | 2011 | 2649 | 0.260 |
Why?
|
| Eating | 4 | 2005 | 382 | 0.260 |
Why?
|
| Coronary Disease | 5 | 2011 | 638 | 0.260 |
Why?
|
| Hyperphagia | 2 | 1998 | 46 | 0.250 |
Why?
|
| Social Support | 6 | 2017 | 375 | 0.250 |
Why?
|
| Cohort Studies | 10 | 2021 | 5122 | 0.250 |
Why?
|
| Anorexia Nervosa | 2 | 1996 | 31 | 0.250 |
Why?
|
| Attitude to Health | 4 | 2003 | 251 | 0.250 |
Why?
|
| Cyclobutanes | 4 | 2004 | 7 | 0.240 |
Why?
|
| Mental Processes | 1 | 2005 | 38 | 0.230 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2014 | 848 | 0.230 |
Why?
|
| Inflammation Mediators | 1 | 2007 | 228 | 0.230 |
Why?
|
| Double-Blind Method | 10 | 2019 | 1638 | 0.230 |
Why?
|
| Foods, Specialized | 1 | 2015 | 1 | 0.230 |
Why?
|
| Diet, Diabetic | 1 | 2015 | 6 | 0.230 |
Why?
|
| Cholesterol, LDL | 6 | 2014 | 612 | 0.220 |
Why?
|
| Adolescent Behavior | 1 | 2007 | 170 | 0.220 |
Why?
|
| Diabetic Angiopathies | 1 | 2015 | 67 | 0.220 |
Why?
|
| Psychological Tests | 2 | 2011 | 94 | 0.220 |
Why?
|
| Parent-Child Relations | 2 | 2007 | 256 | 0.220 |
Why?
|
| Bone Density | 2 | 2012 | 362 | 0.210 |
Why?
|
| Aging | 4 | 2008 | 1266 | 0.210 |
Why?
|
| Self Concept | 4 | 2001 | 163 | 0.210 |
Why?
|
| Ankle Brachial Index | 1 | 2014 | 40 | 0.210 |
Why?
|
| Mental Disorders | 2 | 2011 | 907 | 0.210 |
Why?
|
| Group Processes | 3 | 2019 | 48 | 0.210 |
Why?
|
| Reproducibility of Results | 8 | 2015 | 2991 | 0.210 |
Why?
|
| Severity of Illness Index | 6 | 2016 | 3093 | 0.210 |
Why?
|
| Liver Cirrhosis | 1 | 2011 | 901 | 0.210 |
Why?
|
| Fractures, Bone | 3 | 2017 | 207 | 0.200 |
Why?
|
| Software | 1 | 2008 | 752 | 0.200 |
Why?
|
| Drug Therapy, Combination | 2 | 2017 | 1170 | 0.200 |
Why?
|
| Nutrition Policy | 2 | 2015 | 91 | 0.200 |
Why?
|
| Analysis of Variance | 9 | 2006 | 955 | 0.200 |
Why?
|
| Time Factors | 14 | 2017 | 6280 | 0.200 |
Why?
|
| Holistic Health | 1 | 2003 | 12 | 0.190 |
Why?
|
| Indians, North American | 1 | 2003 | 74 | 0.190 |
Why?
|
| Diet Records | 3 | 2013 | 70 | 0.190 |
Why?
|
| Parents | 3 | 2015 | 1120 | 0.190 |
Why?
|
| Personality Tests | 2 | 2000 | 17 | 0.190 |
Why?
|
| Primary Health Care | 3 | 2006 | 791 | 0.190 |
Why?
|
| Chemokine CCL2 | 2 | 2013 | 114 | 0.190 |
Why?
|
| Social Class | 2 | 2011 | 212 | 0.190 |
Why?
|
| Multivariate Analysis | 4 | 2017 | 1406 | 0.180 |
Why?
|
| Fenfluramine | 3 | 2002 | 12 | 0.180 |
Why?
|
| Biomarkers | 6 | 2014 | 3407 | 0.180 |
Why?
|
| Risk | 5 | 2012 | 739 | 0.180 |
Why?
|
| Antihypertensive Agents | 1 | 2015 | 422 | 0.180 |
Why?
|
| Dyslipidemias | 2 | 2016 | 247 | 0.170 |
Why?
|
| Restaurants | 2 | 2010 | 13 | 0.170 |
Why?
|
| Prejudice | 1 | 2001 | 40 | 0.170 |
Why?
|
| Mammography | 2 | 2009 | 131 | 0.170 |
Why?
|
| Stress, Psychological | 5 | 2010 | 564 | 0.170 |
Why?
|
| Longitudinal Studies | 6 | 2014 | 1518 | 0.170 |
Why?
|
| Prospective Studies | 9 | 2010 | 6507 | 0.170 |
Why?
|
| Alleles | 3 | 2012 | 1711 | 0.170 |
Why?
|
| Cost Savings | 1 | 2021 | 78 | 0.170 |
Why?
|
| Proportional Hazards Models | 5 | 2017 | 1405 | 0.160 |
Why?
|
| Women's Health | 2 | 2008 | 143 | 0.160 |
Why?
|
| Dexfenfluramine | 1 | 2000 | 3 | 0.160 |
Why?
|
| Serotonin Receptor Agonists | 1 | 2000 | 20 | 0.160 |
Why?
|
| Delayed-Action Preparations | 3 | 2016 | 118 | 0.160 |
Why?
|
| Anxiety | 2 | 2011 | 1030 | 0.160 |
Why?
|
| Legislation, Medical | 1 | 2000 | 14 | 0.160 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2015 | 2860 | 0.160 |
Why?
|
| Peptide Hormones | 2 | 2013 | 71 | 0.160 |
Why?
|
| Prevalence | 7 | 2017 | 2695 | 0.160 |
Why?
|
| Odds Ratio | 4 | 2014 | 1235 | 0.160 |
Why?
|
| Mentors | 1 | 2021 | 160 | 0.150 |
Why?
|
| Pediatric Obesity | 2 | 2015 | 411 | 0.150 |
Why?
|
| Heart Rate | 1 | 2012 | 580 | 0.150 |
Why?
|
| Food, Formulated | 4 | 2008 | 38 | 0.150 |
Why?
|
| Personal Satisfaction | 2 | 2012 | 102 | 0.150 |
Why?
|
| Tumor Necrosis Factor-alpha | 3 | 2013 | 643 | 0.150 |
Why?
|
| Genetic Predisposition to Disease | 5 | 2015 | 3416 | 0.150 |
Why?
|
| Program Evaluation | 5 | 2010 | 443 | 0.150 |
Why?
|
| Hormone Replacement Therapy | 2 | 2010 | 215 | 0.150 |
Why?
|
| Risk Assessment | 6 | 2014 | 3696 | 0.150 |
Why?
|
| Hysterectomy | 1 | 2011 | 205 | 0.150 |
Why?
|
| Calcium Compounds | 1 | 2008 | 7 | 0.150 |
Why?
|
| Chi-Square Distribution | 4 | 2011 | 570 | 0.150 |
Why?
|
| Principal Component Analysis | 1 | 2009 | 153 | 0.150 |
Why?
|
| Family | 4 | 2003 | 593 | 0.150 |
Why?
|
| Logistic Models | 5 | 2014 | 1838 | 0.150 |
Why?
|
| Environment | 1 | 1999 | 149 | 0.140 |
Why?
|
| Vitamins | 1 | 2019 | 115 | 0.140 |
Why?
|
| Patient Participation | 2 | 2013 | 244 | 0.140 |
Why?
|
| Estrogens | 1 | 2011 | 436 | 0.140 |
Why?
|
| Calcium, Dietary | 1 | 2008 | 37 | 0.140 |
Why?
|
| Self Efficacy | 1 | 1999 | 205 | 0.140 |
Why?
|
| Recurrence | 6 | 1999 | 1483 | 0.140 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2008 | 87 | 0.140 |
Why?
|
| Bone Density Conservation Agents | 1 | 2008 | 58 | 0.140 |
Why?
|
| Fruit | 2 | 2009 | 234 | 0.140 |
Why?
|
| Anniversaries and Special Events | 1 | 2017 | 10 | 0.140 |
Why?
|
| Health Status Disparities | 1 | 2011 | 277 | 0.130 |
Why?
|
| Personality | 3 | 2002 | 115 | 0.130 |
Why?
|
| Child, Preschool | 9 | 2013 | 15051 | 0.130 |
Why?
|
| Alcohol Drinking | 5 | 2008 | 347 | 0.130 |
Why?
|
| Pilot Projects | 2 | 2021 | 1457 | 0.130 |
Why?
|
| Predictive Value of Tests | 4 | 2011 | 2298 | 0.130 |
Why?
|
| Healthy Lifestyle | 1 | 2017 | 33 | 0.130 |
Why?
|
| Habits | 2 | 2011 | 28 | 0.130 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2019 | 904 | 0.130 |
Why?
|
| Prognosis | 6 | 2014 | 4953 | 0.130 |
Why?
|
| ROC Curve | 1 | 2018 | 623 | 0.120 |
Why?
|
| Lost to Follow-Up | 1 | 2016 | 32 | 0.120 |
Why?
|
| Feasibility Studies | 2 | 2017 | 838 | 0.120 |
Why?
|
| Activities of Daily Living | 1 | 2008 | 409 | 0.120 |
Why?
|
| Sodium, Dietary | 2 | 2010 | 30 | 0.120 |
Why?
|
| Reference Values | 4 | 2013 | 692 | 0.120 |
Why?
|
| Leptin | 4 | 2013 | 219 | 0.120 |
Why?
|
| Cross-Sectional Studies | 6 | 2013 | 3836 | 0.110 |
Why?
|
| Food | 2 | 1994 | 125 | 0.110 |
Why?
|
| Acculturation | 1 | 2015 | 61 | 0.110 |
Why?
|
| Absorptiometry, Photon | 3 | 2015 | 199 | 0.110 |
Why?
|
| Lipase | 4 | 2003 | 88 | 0.110 |
Why?
|
| Military Personnel | 2 | 2008 | 210 | 0.110 |
Why?
|
| Physical Exertion | 5 | 2007 | 67 | 0.110 |
Why?
|
| Adipose Tissue | 2 | 2008 | 495 | 0.110 |
Why?
|
| Socioeconomic Factors | 4 | 2010 | 898 | 0.110 |
Why?
|
| Caffeine | 2 | 2013 | 67 | 0.110 |
Why?
|
| Monitoring, Physiologic | 2 | 2014 | 371 | 0.110 |
Why?
|
| Dietary Proteins | 2 | 2012 | 216 | 0.110 |
Why?
|
| Pandemics | 1 | 2022 | 1165 | 0.110 |
Why?
|
| Health Services | 1 | 2014 | 68 | 0.110 |
Why?
|
| Neoplasms | 2 | 2020 | 2966 | 0.110 |
Why?
|
| Child Nutritional Physiological Phenomena | 2 | 2012 | 157 | 0.110 |
Why?
|
| Nutritional Status | 2 | 2011 | 303 | 0.110 |
Why?
|
| Health Services Accessibility | 1 | 2020 | 698 | 0.110 |
Why?
|
| Clinical Trials as Topic | 3 | 2006 | 1139 | 0.100 |
Why?
|
| Dextrins | 1 | 2013 | 1 | 0.100 |
Why?
|
| Satiety Response | 2 | 2009 | 31 | 0.100 |
Why?
|
| Tea | 1 | 2013 | 18 | 0.100 |
Why?
|
| Placebos | 4 | 2014 | 227 | 0.100 |
Why?
|
| Plants, Toxic | 1 | 1993 | 6 | 0.100 |
Why?
|
| Brain | 1 | 2005 | 3235 | 0.100 |
Why?
|
| Trans Fatty Acids | 1 | 2013 | 13 | 0.100 |
Why?
|
| Dietary Sucrose | 1 | 2013 | 41 | 0.100 |
Why?
|
| Tobacco, Smokeless | 1 | 1993 | 10 | 0.100 |
Why?
|
| Mortality | 1 | 2014 | 261 | 0.100 |
Why?
|
| United Kingdom | 1 | 2013 | 255 | 0.100 |
Why?
|
| Epidemics | 1 | 2013 | 58 | 0.100 |
Why?
|
| Taste | 2 | 2011 | 28 | 0.090 |
Why?
|
| Adolescent Nutritional Physiological Phenomena | 1 | 2012 | 33 | 0.090 |
Why?
|
| Linear Models | 3 | 2009 | 695 | 0.090 |
Why?
|
| Primary Prevention | 1 | 1993 | 175 | 0.090 |
Why?
|
| Cognitive Dysfunction | 1 | 2017 | 355 | 0.090 |
Why?
|
| Drug Combinations | 3 | 2010 | 280 | 0.090 |
Why?
|
| Cellular Senescence | 1 | 2014 | 218 | 0.090 |
Why?
|
| Plant Extracts | 1 | 2013 | 139 | 0.090 |
Why?
|
| Leukocyte Count | 1 | 2012 | 248 | 0.090 |
Why?
|
| Affect | 3 | 2007 | 170 | 0.090 |
Why?
|
| Cultural Characteristics | 1 | 1991 | 44 | 0.090 |
Why?
|
| Dietary Carbohydrates | 3 | 2009 | 108 | 0.090 |
Why?
|
| Louisiana | 1 | 2011 | 136 | 0.090 |
Why?
|
| Psychology, Child | 1 | 2011 | 43 | 0.090 |
Why?
|
| Health Care Costs | 1 | 2014 | 400 | 0.080 |
Why?
|
| Waist-Hip Ratio | 2 | 2008 | 54 | 0.080 |
Why?
|
| Food Preferences | 1 | 2011 | 114 | 0.080 |
Why?
|
| Knee | 1 | 2010 | 21 | 0.080 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2019 | 1078 | 0.080 |
Why?
|
| Disability Evaluation | 2 | 2012 | 197 | 0.080 |
Why?
|
| Monocytes | 1 | 2012 | 337 | 0.080 |
Why?
|
| Down-Regulation | 1 | 2012 | 659 | 0.080 |
Why?
|
| Edible Grain | 1 | 2009 | 43 | 0.070 |
Why?
|
| Universities | 1 | 2010 | 122 | 0.070 |
Why?
|
| Osteoporosis, Postmenopausal | 1 | 2009 | 31 | 0.070 |
Why?
|
| Mexico | 1 | 2009 | 198 | 0.070 |
Why?
|
| Disease Management | 2 | 2016 | 564 | 0.070 |
Why?
|
| England | 1 | 2008 | 58 | 0.070 |
Why?
|
| Colorectal Neoplasms | 2 | 2011 | 639 | 0.070 |
Why?
|
| Enzyme Inhibitors | 2 | 2003 | 566 | 0.070 |
Why?
|
| Electronic Mail | 1 | 2008 | 41 | 0.070 |
Why?
|
| Suicidal Ideation | 1 | 2011 | 258 | 0.070 |
Why?
|
| Algorithms | 2 | 2010 | 1685 | 0.070 |
Why?
|
| Rats | 3 | 2011 | 3460 | 0.070 |
Why?
|
| Forecasting | 4 | 2000 | 361 | 0.070 |
Why?
|
| Cognition | 2 | 2007 | 845 | 0.070 |
Why?
|
| Child Nutrition Sciences | 1 | 2007 | 18 | 0.070 |
Why?
|
| Exercise Test | 2 | 2015 | 243 | 0.070 |
Why?
|
| Proteins | 2 | 1998 | 1027 | 0.070 |
Why?
|
| Mass Screening | 1 | 2013 | 825 | 0.070 |
Why?
|
| Cytokines | 1 | 2013 | 1348 | 0.070 |
Why?
|
| Problem Solving | 1 | 2007 | 65 | 0.070 |
Why?
|
| Bulimia Nervosa | 1 | 2007 | 1 | 0.070 |
Why?
|
| Motivation | 1 | 2010 | 332 | 0.070 |
Why?
|
| Role | 1 | 1987 | 28 | 0.060 |
Why?
|
| Self-Help Devices | 1 | 2007 | 10 | 0.060 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type II | 1 | 2007 | 16 | 0.060 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type I | 1 | 2007 | 33 | 0.060 |
Why?
|
| Lipopolysaccharide Receptors | 1 | 2007 | 53 | 0.060 |
Why?
|
| Urban Population | 2 | 2011 | 281 | 0.060 |
Why?
|
| Goals | 1 | 2007 | 125 | 0.060 |
Why?
|
| Receptors, Interleukin-6 | 1 | 2007 | 40 | 0.060 |
Why?
|
| User-Computer Interface | 1 | 2008 | 161 | 0.060 |
Why?
|
| Family Therapy | 1 | 1987 | 34 | 0.060 |
Why?
|
| Age Factors | 3 | 2009 | 2872 | 0.060 |
Why?
|
| Secondary Prevention | 2 | 2005 | 220 | 0.060 |
Why?
|
| Probability | 1 | 1987 | 310 | 0.060 |
Why?
|
| Cell Differentiation | 1 | 2014 | 1948 | 0.060 |
Why?
|
| Sex Factors | 3 | 2009 | 1347 | 0.060 |
Why?
|
| Treatment Failure | 2 | 2019 | 353 | 0.060 |
Why?
|
| Hip Fractures | 2 | 2011 | 68 | 0.060 |
Why?
|
| Genetic Research | 1 | 2006 | 56 | 0.060 |
Why?
|
| Confidence Intervals | 2 | 2014 | 272 | 0.060 |
Why?
|
| Lipoproteins | 3 | 2016 | 183 | 0.060 |
Why?
|
| Animals | 6 | 2013 | 34404 | 0.060 |
Why?
|
| Anthropometry | 2 | 2008 | 190 | 0.060 |
Why?
|
| Learning | 1 | 2008 | 373 | 0.060 |
Why?
|
| Heart Diseases | 3 | 1986 | 505 | 0.060 |
Why?
|
| T-Lymphocytes | 1 | 2014 | 1790 | 0.060 |
Why?
|
| Physician's Role | 1 | 1987 | 165 | 0.060 |
Why?
|
| Snacks | 1 | 2015 | 20 | 0.060 |
Why?
|
| Evaluation Studies as Topic | 3 | 1998 | 235 | 0.050 |
Why?
|
| Data Accuracy | 1 | 2014 | 31 | 0.050 |
Why?
|
| Policy Making | 1 | 2014 | 59 | 0.050 |
Why?
|
| Meals | 1 | 2015 | 62 | 0.050 |
Why?
|
| Observational Studies as Topic | 1 | 2014 | 99 | 0.050 |
Why?
|
| Up-Regulation | 1 | 2007 | 832 | 0.050 |
Why?
|
| Adrenergic Uptake Inhibitors | 1 | 2004 | 29 | 0.050 |
Why?
|
| Adaptation, Psychological | 2 | 1997 | 437 | 0.050 |
Why?
|
| Somatoform Disorders | 1 | 2003 | 46 | 0.050 |
Why?
|
| Treatment Refusal | 1 | 2003 | 78 | 0.050 |
Why?
|
| Discriminant Analysis | 1 | 2003 | 22 | 0.050 |
Why?
|
| Cholesterol, Dietary | 5 | 1986 | 48 | 0.050 |
Why?
|
| Informed Consent | 1 | 2006 | 343 | 0.050 |
Why?
|
| Carotid Stenosis | 1 | 2014 | 106 | 0.050 |
Why?
|
| Retrospective Studies | 2 | 2017 | 17662 | 0.050 |
Why?
|
| Drug Administration Schedule | 2 | 2008 | 741 | 0.050 |
Why?
|
| Cardiovascular System | 1 | 2004 | 103 | 0.050 |
Why?
|
| Single-Blind Method | 2 | 2014 | 241 | 0.050 |
Why?
|
| Receptor, Melatonin, MT1 | 1 | 2012 | 1 | 0.050 |
Why?
|
| Receptor, Melatonin, MT2 | 1 | 2012 | 3 | 0.050 |
Why?
|
| Health Policy | 1 | 2014 | 227 | 0.050 |
Why?
|
| Transcription Factor 7-Like 2 Protein | 1 | 2012 | 25 | 0.050 |
Why?
|
| Dairy Products | 1 | 2012 | 43 | 0.050 |
Why?
|
| Mobility Limitation | 1 | 2012 | 35 | 0.050 |
Why?
|
| Diet Surveys | 1 | 2012 | 101 | 0.050 |
Why?
|
| Comorbidity | 2 | 2014 | 1600 | 0.050 |
Why?
|
| Insulin Receptor Substrate Proteins | 1 | 2012 | 72 | 0.040 |
Why?
|
| Co-Repressor Proteins | 1 | 2012 | 38 | 0.040 |
Why?
|
| MEDLINE | 1 | 2001 | 18 | 0.040 |
Why?
|
| Waist Circumference | 1 | 2012 | 95 | 0.040 |
Why?
|
| Leisure Activities | 1 | 2001 | 10 | 0.040 |
Why?
|
| Angiotensinogen | 1 | 2001 | 24 | 0.040 |
Why?
|
| Poverty Areas | 1 | 2011 | 36 | 0.040 |
Why?
|
| Sampling Studies | 1 | 2001 | 75 | 0.040 |
Why?
|
| Precision Medicine | 1 | 2015 | 378 | 0.040 |
Why?
|
| Interviews as Topic | 2 | 2017 | 440 | 0.040 |
Why?
|
| Peptidyl-Dipeptidase A | 1 | 2001 | 56 | 0.040 |
Why?
|
| Africa | 1 | 2001 | 141 | 0.040 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2012 | 792 | 0.040 |
Why?
|
| Controlled Clinical Trials as Topic | 1 | 2000 | 13 | 0.040 |
Why?
|
| GTP-Binding Proteins | 1 | 2001 | 161 | 0.040 |
Why?
|
| Random Allocation | 2 | 1999 | 423 | 0.040 |
Why?
|
| Occupational Health Services | 1 | 1980 | 5 | 0.040 |
Why?
|
| Lipoproteins, HDL | 4 | 2005 | 97 | 0.040 |
Why?
|
| Nutrition Disorders | 1 | 1980 | 27 | 0.040 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2020 | 126 | 0.040 |
Why?
|
| Health Surveys | 1 | 2001 | 263 | 0.040 |
Why?
|
| Cross-Over Studies | 1 | 2001 | 331 | 0.040 |
Why?
|
| Fatty Acids, Unsaturated | 2 | 2013 | 67 | 0.040 |
Why?
|
| Peripheral Arterial Disease | 1 | 2014 | 314 | 0.040 |
Why?
|
| Science | 1 | 2000 | 36 | 0.040 |
Why?
|
| Antidepressive Agents | 2 | 2014 | 332 | 0.040 |
Why?
|
| Venous Thrombosis | 1 | 2011 | 168 | 0.040 |
Why?
|
| Lymphatic Metastasis | 1 | 2010 | 433 | 0.040 |
Why?
|
| Young Adult | 3 | 2021 | 10099 | 0.040 |
Why?
|
| Videoconferencing | 1 | 2019 | 21 | 0.040 |
Why?
|
| Neurotoxicity Syndromes | 1 | 2000 | 66 | 0.040 |
Why?
|
| Causality | 1 | 2009 | 92 | 0.040 |
Why?
|
| Walking Speed | 1 | 2018 | 18 | 0.040 |
Why?
|
| Hand Strength | 1 | 2018 | 59 | 0.040 |
Why?
|
| Neoplasm Invasiveness | 1 | 2010 | 646 | 0.040 |
Why?
|
| Statistics as Topic | 1 | 1999 | 244 | 0.040 |
Why?
|
| Receptors, Dopamine D2 | 1 | 1998 | 41 | 0.040 |
Why?
|
| Heart Valve Diseases | 1 | 2000 | 174 | 0.030 |
Why?
|
| Sick Leave | 1 | 1997 | 6 | 0.030 |
Why?
|
| Infant | 3 | 2012 | 13317 | 0.030 |
Why?
|
| Neoplasm Proteins | 1 | 2012 | 677 | 0.030 |
Why?
|
| Pulse | 1 | 1997 | 27 | 0.030 |
Why?
|
| Pedigree | 1 | 2001 | 1712 | 0.030 |
Why?
|
| Mental Status Schedule | 1 | 2017 | 43 | 0.030 |
Why?
|
| Disease-Free Survival | 1 | 2019 | 910 | 0.030 |
Why?
|
| Social Facilitation | 1 | 1996 | 2 | 0.030 |
Why?
|
| beta-Endorphin | 1 | 1996 | 11 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2019 | 709 | 0.030 |
Why?
|
| Cholecystokinin | 1 | 1996 | 12 | 0.030 |
Why?
|
| Multicenter Studies as Topic | 2 | 2009 | 300 | 0.030 |
Why?
|
| Age Distribution | 1 | 1998 | 429 | 0.030 |
Why?
|
| Social Values | 1 | 1996 | 46 | 0.030 |
Why?
|
| Neoplasm Staging | 1 | 2010 | 1322 | 0.030 |
Why?
|
| Norepinephrine | 1 | 1996 | 156 | 0.030 |
Why?
|
| Aged, 80 and over | 2 | 2018 | 6915 | 0.030 |
Why?
|
| Personality Disorders | 1 | 1999 | 172 | 0.030 |
Why?
|
| Models, Biological | 1 | 2001 | 1395 | 0.030 |
Why?
|
| Nevada | 1 | 1995 | 2 | 0.030 |
Why?
|
| Genotype | 1 | 2012 | 2656 | 0.030 |
Why?
|
| Body Constitution | 1 | 1995 | 42 | 0.030 |
Why?
|
| Exons | 1 | 1998 | 769 | 0.030 |
Why?
|
| Fertility | 1 | 1998 | 266 | 0.030 |
Why?
|
| Attitude | 1 | 1996 | 112 | 0.030 |
Why?
|
| Serotonin | 1 | 1996 | 212 | 0.030 |
Why?
|
| Potassium Channels, Voltage-Gated | 1 | 2015 | 63 | 0.030 |
Why?
|
| Internal-External Control | 1 | 1995 | 74 | 0.030 |
Why?
|
| Genotyping Techniques | 1 | 2015 | 110 | 0.030 |
Why?
|
| Behavior, Addictive | 1 | 1995 | 59 | 0.030 |
Why?
|
| Dopamine | 1 | 1996 | 256 | 0.030 |
Why?
|
| Research Support as Topic | 1 | 1995 | 61 | 0.030 |
Why?
|
| Polymorphism, Genetic | 1 | 1998 | 794 | 0.030 |
Why?
|
| Hypertension, Pulmonary | 1 | 2000 | 463 | 0.030 |
Why?
|
| Research | 1 | 1996 | 269 | 0.030 |
Why?
|
| Hyperlipidemias | 3 | 1984 | 188 | 0.030 |
Why?
|
| Emotions | 1 | 1997 | 367 | 0.030 |
Why?
|
| Phentermine | 2 | 2008 | 7 | 0.030 |
Why?
|
| Keratosis | 1 | 1994 | 18 | 0.030 |
Why?
|
| Sunlight | 1 | 1994 | 27 | 0.030 |
Why?
|
| Genetic Testing | 1 | 2001 | 1101 | 0.030 |
Why?
|
| Smoking Prevention | 2 | 1992 | 33 | 0.030 |
Why?
|
| Walking | 1 | 1996 | 234 | 0.030 |
Why?
|
| Running | 3 | 1986 | 32 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 1999 | 2146 | 0.030 |
Why?
|
| Suggestion | 1 | 1973 | 6 | 0.030 |
Why?
|
| DNA-Binding Proteins | 1 | 2012 | 1965 | 0.030 |
Why?
|
| Zea mays | 1 | 2013 | 22 | 0.020 |
Why?
|
| Cost of Illness | 1 | 1995 | 291 | 0.020 |
Why?
|
| Fatty Acids, Monounsaturated | 1 | 2013 | 50 | 0.020 |
Why?
|
| Stroke | 1 | 2011 | 1049 | 0.020 |
Why?
|
| Teaching Materials | 1 | 1992 | 18 | 0.020 |
Why?
|
| Immunologic Memory | 1 | 2014 | 202 | 0.020 |
Why?
|
| Personality Assessment | 1 | 1993 | 112 | 0.020 |
Why?
|
| Food Supply | 1 | 2013 | 91 | 0.020 |
Why?
|
| Fat Substitutes | 1 | 1992 | 1 | 0.020 |
Why?
|
| Nutritive Value | 1 | 2012 | 83 | 0.020 |
Why?
|
| Genetic Association Studies | 1 | 2015 | 838 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2014 | 769 | 0.020 |
Why?
|
| Smoking | 3 | 1993 | 926 | 0.020 |
Why?
|
| Ethanol | 3 | 1990 | 164 | 0.020 |
Why?
|
| Interleukin-6 | 1 | 2013 | 419 | 0.020 |
Why?
|
| Rats, Inbred Strains | 2 | 1989 | 199 | 0.020 |
Why?
|
| Nutrition Surveys | 1 | 2013 | 327 | 0.020 |
Why?
|
| Appetite Regulation | 1 | 1991 | 44 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2008 | 3451 | 0.020 |
Why?
|
| Aversive Therapy | 1 | 1971 | 1 | 0.020 |
Why?
|
| Reference Standards | 1 | 2012 | 231 | 0.020 |
Why?
|
| Precancerous Conditions | 1 | 1994 | 283 | 0.020 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2014 | 460 | 0.020 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2014 | 496 | 0.020 |
Why?
|
| Students | 1 | 1993 | 251 | 0.020 |
Why?
|
| Decision Support Techniques | 1 | 2013 | 298 | 0.020 |
Why?
|
| Apolipoproteins A | 2 | 1990 | 53 | 0.020 |
Why?
|
| Fatty Acids | 1 | 2013 | 377 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2011 | 432 | 0.020 |
Why?
|
| Smoking Cessation | 1 | 1992 | 190 | 0.020 |
Why?
|
| Models, Theoretical | 2 | 1995 | 366 | 0.020 |
Why?
|
| Forensic Psychiatry | 1 | 1970 | 15 | 0.020 |
Why?
|
| Lipoprotein Lipase | 1 | 1990 | 62 | 0.020 |
Why?
|
| Narcotic Antagonists | 1 | 2010 | 112 | 0.020 |
Why?
|
| Macrophages | 1 | 2013 | 665 | 0.020 |
Why?
|
| Medical Records | 1 | 1970 | 181 | 0.020 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2010 | 393 | 0.020 |
Why?
|
| Spinal Fractures | 1 | 2009 | 46 | 0.020 |
Why?
|
| Conditioning, Operant | 1 | 1968 | 17 | 0.020 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 1994 | 759 | 0.020 |
Why?
|
| Genome-Wide Association Study | 1 | 2015 | 1844 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2008 | 1626 | 0.020 |
Why?
|
| Oxidative Stress | 1 | 2013 | 807 | 0.020 |
Why?
|
| Morpholines | 1 | 2008 | 68 | 0.020 |
Why?
|
| Massachusetts | 1 | 2008 | 118 | 0.020 |
Why?
|
| Accidental Falls | 1 | 2009 | 118 | 0.020 |
Why?
|
| Military Medicine | 1 | 2008 | 51 | 0.020 |
Why?
|
| Avoidance Learning | 1 | 1968 | 63 | 0.020 |
Why?
|
| Radioimmunoassay | 1 | 2006 | 99 | 0.020 |
Why?
|
| Chronic Disease | 2 | 2002 | 1235 | 0.020 |
Why?
|
| Skin Neoplasms | 1 | 1994 | 904 | 0.020 |
Why?
|
| Ghrelin | 1 | 2006 | 58 | 0.020 |
Why?
|
| Anxiety Disorders | 1 | 1993 | 744 | 0.020 |
Why?
|
| Food Handling | 1 | 1986 | 14 | 0.020 |
Why?
|
| Ethics Committees, Research | 1 | 2006 | 29 | 0.010 |
Why?
|
| Ethics, Research | 1 | 2006 | 55 | 0.010 |
Why?
|
| Pregnancy | 1 | 1998 | 7576 | 0.010 |
Why?
|
| Survival Analysis | 1 | 2008 | 1521 | 0.010 |
Why?
|
| Circadian Rhythm | 1 | 2007 | 316 | 0.010 |
Why?
|
| Inflammation | 1 | 2012 | 1493 | 0.010 |
Why?
|
| Sports Medicine | 1 | 1983 | 30 | 0.010 |
Why?
|
| Culture | 2 | 1994 | 69 | 0.010 |
Why?
|
| Demography | 1 | 2003 | 243 | 0.010 |
Why?
|
| Missouri | 1 | 2002 | 41 | 0.010 |
Why?
|
| Benzphetamine | 1 | 2002 | 1 | 0.010 |
Why?
|
| Amphetamines | 1 | 2002 | 9 | 0.010 |
Why?
|
| Weight Lifting | 1 | 2001 | 3 | 0.010 |
Why?
|
| Liver | 1 | 1990 | 1799 | 0.010 |
Why?
|
| Physical Endurance | 1 | 2001 | 42 | 0.010 |
Why?
|
| Interview, Psychological | 1 | 2002 | 104 | 0.010 |
Why?
|
| Methods | 1 | 1981 | 115 | 0.010 |
Why?
|
| Jogging | 3 | 1990 | 3 | 0.010 |
Why?
|
| Sweden | 1 | 2000 | 58 | 0.010 |
Why?
|
| Ambulatory Care Facilities | 1 | 1982 | 236 | 0.010 |
Why?
|
| Diethylpropion | 1 | 1998 | 1 | 0.010 |
Why?
|
| 1-Naphthylamine | 1 | 1998 | 7 | 0.010 |
Why?
|
| Ephedrine | 1 | 1998 | 5 | 0.010 |
Why?
|
| Audiovisual Aids | 1 | 1978 | 23 | 0.010 |
Why?
|
| Receptors, Dopamine D4 | 1 | 1998 | 5 | 0.010 |
Why?
|
| Fluoxetine | 1 | 1998 | 45 | 0.010 |
Why?
|
| Apolipoprotein A-I | 2 | 1990 | 80 | 0.010 |
Why?
|
| Sertraline | 1 | 1998 | 46 | 0.010 |
Why?
|
| Adrenergic beta-Agonists | 1 | 1998 | 79 | 0.010 |
Why?
|
| Arousal | 1 | 1998 | 77 | 0.010 |
Why?
|
| Public Policy | 1 | 1998 | 54 | 0.010 |
Why?
|
| Child Welfare | 1 | 1998 | 68 | 0.010 |
Why?
|
| Personality Inventory | 1 | 1998 | 179 | 0.010 |
Why?
|
| Television | 1 | 1998 | 70 | 0.010 |
Why?
|
| Hypercholesterolemia | 1 | 1979 | 234 | 0.010 |
Why?
|
| Conditioning, Classical | 1 | 1971 | 53 | 0.010 |
Why?
|
| Lipoproteins, HDL2 | 1 | 1990 | 2 | 0.010 |
Why?
|
| Lipoproteins, HDL3 | 1 | 1990 | 2 | 0.010 |
Why?
|
| Psychiatric Department, Hospital | 1 | 1970 | 23 | 0.000 |
Why?
|
| Smell | 1 | 1971 | 133 | 0.000 |
Why?
|
| Hospitals, Psychiatric | 1 | 1970 | 70 | 0.000 |
Why?
|
| Hospitals, Teaching | 1 | 1970 | 109 | 0.000 |
Why?
|
| Menu Planning | 2 | 1979 | 8 | 0.000 |
Why?
|
| Type A Personality | 1 | 1987 | 3 | 0.000 |
Why?
|
| Relaxation Therapy | 1 | 1987 | 24 | 0.000 |
Why?
|
| Biofeedback, Psychology | 1 | 1987 | 38 | 0.000 |
Why?
|
| Social Environment | 1 | 1987 | 122 | 0.000 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 1987 | 215 | 0.000 |
Why?
|
| Referral and Consultation | 1 | 1970 | 564 | 0.000 |
Why?
|
| Length of Stay | 1 | 1970 | 1399 | 0.000 |
Why?
|
| Rest | 1 | 1983 | 63 | 0.000 |
Why?
|
| Hospitalization | 1 | 1970 | 1942 | 0.000 |
Why?
|
| Eggs | 1 | 1980 | 22 | 0.000 |
Why?
|
| Alcoholic Beverages | 1 | 1980 | 17 | 0.000 |
Why?
|
| Food Analysis | 1 | 1979 | 23 | 0.000 |
Why?
|
| Costs and Cost Analysis | 1 | 1979 | 155 | 0.000 |
Why?
|
| Lipoproteins, VLDL | 1 | 1977 | 53 | 0.000 |
Why?
|
| Infant, Newborn | 1 | 1978 | 8594 | 0.000 |
Why?
|